The Anti-Rheumatic Drug, Leflunomide, Induces Nephrotoxicity in Mice via Upregulation of TGFβ-Mediated p53/Smad2/3 Signaling
"> Figure 1
<p>Network protein–protein interaction analysis for TGFβ and Smad proteins as presented by the STRING database.</p> "> Figure 2
<p>TGFβ-induced Smad signaling, created via Reactome and KEGG bioinformatic data bases.</p> "> Figure 3
<p>Effect of LEFN on kidney function parameters in adult mice. (<b>A</b>) Serum creatinine, (<b>B</b>) BUN. Data are mean ± SD, and analysis was performed by applying one-way ANOVA and Bonferroni’s test at <span class="html-italic">p</span> < 0.05. †: versus the vehicle group, ‡: versus the LEFN 2.5 mg/kg group, and Σ: versus the LEFN 5 mg/kg group. BUN: blood urea nitrogen.</p> "> Figure 4
<p>Histopathologic scores for hematoxylin and eosin-stained kidney specimens in mice treated with LEFN. Panel (<b>A1</b>,<b>A2</b>) show sections of kidney tissue in the vehicle group, showing regular tubules (dashed arrow) lined by epithelial cells with intact eosinophilic cytoplasm and regular nuclei, and glomeruli (arrowhead) showing capillary tuft with a thin wall and thin patent Bowman’s space and mesangial cells. Interstitium showed thin blood vessels (curved arrow) and loose intervening stroma. Panel (<b>B1</b>,<b>B2</b>) are kidneys from the LEFN 2.5 mg/kg group showing mild focal tubular (dashed arrow) hydropic degeneration of tubular epithelial cells, glomeruli (arrowhead) showing average normal cellularity, and stroma showing focal minimal lymphocytic inflammatory infiltrate (arrow). Panel (<b>C1</b>,<b>C2</b>) are for kidneys in the LEFN 5 mg/kg group showing moderate tubular (dashed arrow) hydropic and vacuolar degeneration of tubular epithelial cells, glomeruli (arrowhead) showing a slight increase in cellularity, and stroma showing focal mild congestion (curved arrow) and focal mild lymphocytic inflammatory infiltrate (arrow). Panel (<b>D1</b>,<b>D2</b>), the LEFN 10 mg/kg group showed moderate hydropic degeneration of tubular epithelial cells (dashed arrow), and glomeruli showed a moderate increase in cellularity with irregularity and focal shrinkage (arrowhead). There is interstitial congestion and focal hemorrhage (curved arrow) with moderate lymphocytic inflammatory infiltrate (arrow), ×100 and ×400, respectively.</p> "> Figure 5
<p>Histopathologic scores for hematoxylin and eosin-stained kidney specimens in mice treated with LEFN. Scores for (<b>A</b>) lymphocytic infiltrate, (<b>B</b>) congestion and hemorrhage, (<b>C</b>) glomerular degeneration, and (<b>D</b>) tubular degeneration. A score from 0–5 was given to each sample, and scores are presented as medians and quartiles, and compared by Kruskal–Wallis ANOVA and Dunn’s test at <span class="html-italic">p</span> < 0.05. *: versus the vehicle group.</p> "> Figure 6
<p>Periodic acid–Schiff staining for the kidney specimen. (<b>A</b>) Sections in kidney tissue from vehicle group showing (left panel) glomerulus with thin basement membranes (black arrow) and patent vascular lumen, and tubules showing (right panel) a preserved brush border (black arrow) of tubular epithelial cells with average cytoplasm (red arrow). (<b>B</b>) Sections in kidney tissue from the LEFN 2.5 mg/kg group showing (left panel) glomerulus with thin basement membranes (black arrow) and patent vascular lumen, and tubules showing (right panel) a focally disrupted and effaced brush border (black arrow) of tubular epithelial cells and early cytoplasmic vacuoles (red arrow). (<b>C</b>) Sections in kidney tissue from the LEFN 5 mg/kg group showing (left panel) glomerular irregularities of vascular lumens with focal increased cellularity (red arrow), but with thin basement membranes (black arrow) (right panel) showing a disrupted and effaced brush border (black arrow) of tubular epithelial cells with moderate cytoplasmic vacuolation (red arrow). (<b>D</b>) Sections in kidney tissue from the LEFN 10 mg/kg group showing (left panel) a mild glomerular increase in cellularity (red arrow) with thin basement membranes (black arrow); the right panel shows multiple intratubular eosinophilic hyaline casts filling tubules (black arrow), with marked disruption of lining epithelial cells’ brush borders.</p> "> Figure 7
<p>Masson’s trichrome staining for the kidneys of mice treated with LEFN. (<b>A</b>, left panel) Sections in kidney tissue from the vehicle group showing glomerulus and proximal tubules with interstitial tissue showing no deposition of green staining fibers in between, and no fibrosis. (<b>A</b>, right panel) shows distal tubules and a vessel in the center with no perivascular or peritubular collagen deposition (arrow). Sections from the kidneys of the LEFN 2.5 mg/kg group showing (<b>B</b>, left panel) no glomerular deposition of collagen fibers (arrow) (<b>B</b>, right panel) shows areas of congested vessels (arrow) with no or faint perivascular green staining, indicating no fibrosis from the kidneys of the LEFN 2.5 mg/kg group. (<b>C</b>, left panel) Sections in kidney tissues from the LEFN 5 mg/kg group showing peritubular and interstitial mild focal deposition of thin green staining collagen fibers (arrow). (<b>C</b>, right panel) shows areas of perivascular, green-stained collagen fibers deposition (arrow), indicating more localization to perivascular areas in the kidneys of the LEFN 5 mg/kg group. (<b>D</b>, left panel) Sections in kidney tissue from the LEFN 10 mg/kg group showing peritubular and interstitial inflammatory infiltrate with deposition of thin green staining collagen fibers (arrow). (<b>D</b>, right panel) shows wider areas of perivascular, green-stained collagen fibers deposition (arrow), indicating more localization to perivascular areas from the kidneys of the LEFN 10 mg/kg group. (<b>E</b>) Column chart for the mean ± SD of the fibrosis area % as measured in each group kidney sepecimens. †: versus the vehicle group, ‡: versus the LEFN 2.5 mg/kg group, and Σ: versus LEFN the 5 mg/kg group at <span class="html-italic">p</span> < 0.05.</p> "> Figure 8
<p>Immunohistochemistry for TGFβ in kidney specimens from LEFN-treated mice. (<b>A</b>) Sections from the vehicle group show focal weak TGFβ-staining in normal kidneys, localized to periglomerular and peritubular areas (in left panel), and focal minimal staining in perivascular areas (right panel). (<b>B</b>) Sections from the LEFN 2.5 mg/kg group show faint focal staining of TGFβ in periglomerular areas (left panel) and minimal focal weak staining in peritubular areas (arrow in right panel). (<b>C</b>) Sections from the LEFN 5 mg/kg group show moderate staining of TGFβ encircling periglomerular areas (left panel), and this is also seen in perivascular areas or focally in peritubular areas (right panel). (<b>D</b>) Sections from the LEFN 10 mg/kg group show moderate to strong staining of TGFβ, especially in areas surrounded by inflammatory cells infiltrate (left panel), and perivascular and peritubular areas (right panel), arrows in all images indicate positive staining. (<b>E</b>) Column chart for mean ± SD of the stained area % in kidney specimens from the experimental groups. †: versus the vehicle group, ‡: versus the LEFN 2.5 mg/kg group, and Σ: versus the LEFN 5 mg/kg group at <span class="html-italic">p</span> < 0.05.</p> "> Figure 9
<p>Immunohistochemistry for p53 in the kidney specimens. (<b>A</b>) Images from the vehicle group show focal weak p53 staining, localized to periglomerular cells (in left panel) and focal minimal staining in tubular cells (right panel). (<b>B</b>) Images from the LEFN 2.5 mg/kg group show a very faint focal staining of p53 in glomerular areas (left panel) and weak staining in peritubular areas (arrow in right panel). (<b>C</b>) The LEFN 5 mg/kg group showed focal moderate or weaker staining of p53 encircling periglomerular areas (left panel), and this is also seen in peritubular and perivascular areas (right panel). (<b>D</b>) The LEFN 10 mg/kg group revealed moderate to strong staining of p53, with most staining in periglomerular tubules (left panel) and in areas surrounded by inflammatory cells infiltrate (right panel), arrows in all images indicate positive staining (<b>E</b>) Column chart for mean ± SD of the stained area % in kidney specimens from the experimental groups and data were analyzed using one-way ANOVA. †: versus the vehicle group, ‡: versus the LEFN 2.5 mg/kg group, and Σ: versus the LEFN 5 mg/kg group at <span class="html-italic">p</span> < 0.05.</p> "> Figure 10
<p>Western blot analysis for the target proteins. (<b>A</b>) The Western blot gels for p-p53, SMAD2/3, and SMA compared to β-ACTIN. (<b>B</b>,<b>C</b>) Column charts for the p-p53 and SMAD2/3 in the experimental groups. Data are mean ± SD. †: versus the vehicle group, ‡: versus the LEFN 2.5 mg/kg group, and Σ: versus the LEFN 5 mg/kg group at <span class="html-italic">p</span> < 0.05.</p> ">
Abstract
:1. Introduction
2. Materials and Methods
2.1. Signaling Pathway Enrichment Analysis
2.2. Animals
2.3. Design of the Experiment
2.4. Collection of Blood Samples and Kidneys
2.5. Estimation of Renal Function Parameters
2.6. Western Blot Analysis for p-p53 and SMAD2/3 in the Renal Homogenate
2.7. Kidney Histopathology and Immunohistochemistry
2.7.1. Morphometric Analysis of H&E-Stained Sections
2.7.2. Examination of PAS-Stained Sections
2.8. Immunohistochemistry and Image Analysis of TGFβ and p53 in Renal Tissues
2.9. Statistical Analysis
3. Results
3.1. The Bioinformatic Study
3.2. Assessment of Renal Function
3.3. Kidney Histopathology for H&E-Stained Sections and Scoring
3.4. Kidney Histopathology in PAS Stained Sections
3.5. Kidney Histopathology in Masson’s Trichrome Stained Sections
3.6. Immunohistochemical and Image Analysis of TGFβ and p53 Expression in Renal Specimen
3.7. Western Blot Analysis of p-p53 and SMAD2/3 in Renal Homogenates
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Alldred, A.; Emery, P. Leflunomide: A Novel DMARD for the Treatment of Rheumatoid Arthritis. Expert Opin. Pharmacother. 2001, 2, 125–137. [Google Scholar] [CrossRef]
- Kaplan, M.J. Leflunomide Aventis Pharma. Curr. Opin. Investig. Drugs 2001, 2, 222–230. [Google Scholar]
- Elshaer, R.E.; Tawfik, M.K.; Nosseir, N.; El-Ghaiesh, S.H.; Toraih, E.A.; Elsherbiny, N.M.; Zaitone, S.A. Leflunomide-Induced Liver Injury in Mice: Involvement of TLR4 Mediated Activation of PI3K/MTOR/NFκB Pathway. Life Sci. 2019, 235, 116824. [Google Scholar] [CrossRef]
- Raj, R.; Nugent, K. Leflunomide-Induced Interstitial Lung Disease (a Systematic Review). Sarcoidosis Vasc. Diffus. Lung Dis. 2013, 30, 167–176. [Google Scholar]
- Razak, S.A.; Islahudin, F.; Shamsuddin, A.F.; Shahril, N.S. A Study on Leflunomide-Induced Liver Injury in Rheumatoid Arthritis Patients. Res. J. Pharm. Technol. 2013, 6, 556–561. [Google Scholar]
- Shields, M.D.; Skelton, W.P.; Laber, D.A.; Verbosky, M.; Ashraf, N. A Novel Case of Leflunomide-Induced Thrombotic Thrombocytopenic Purpura. J. Hematol. 2021, 10, 139–142. [Google Scholar] [CrossRef]
- Villgran, V.D.; Rabold, E.; Nasrullah, A.; Disilvio, B.; Bajwa, O. Leflunomide-Induced Interstitial Pneumonitis: A Rare Occurrence in a Case without Underlying Lung Disease. Respir. Med. Case Rep. 2021, 33, 101468. [Google Scholar] [CrossRef]
- Xuan, J.; Ren, Z.; Qing, T.; Couch, L.; Shi, L.; Tolleson, W.H.; Guo, L. Mitochondrial Dysfunction Induced by Leflunomide and Its Active Metabolite. Toxicology 2018, 396–397, 33–45. [Google Scholar] [CrossRef] [Green Version]
- Lodhi, R.L.; Maity, S.; Kumar, P.; Saraf, S.A.; Kaithwas, G.; Saha, S. Evaluation of Mechanism of Hepatotoxicity of Leflunomide Using Albino Wistar Rats. Afr. J. Pharm. Pharmacol. 2013, 7, 1625–1631. [Google Scholar] [CrossRef] [Green Version]
- Quee, M.S.; Lee-Sun, N.; Eric, C.Y.C.; Urs, A.B. Oxidative Bioactivation and Toxicity of Leflunomide in Immortalized Human Hepatocytes and Kinetics of the Non-Enzymatic to Its Major Etabolitie, A77 1726. Drug Metab. Lett. 2008, 2, 153–157. [Google Scholar]
- Ren, Z.; Chen, S.; Qing, T.; Xuan, J.; Couch, L.; Yu, D.; Ning, B.; Shi, L.; Guo, L. Endoplasmic Reticulum Stress and MAPK Signaling Pathway Activation Underlie Leflunomide-Induced Toxicity in HepG2 Cells. Toxicology 2017, 392, 11–21. [Google Scholar] [CrossRef] [Green Version]
- El-Sherbiny, M.; Atef, H.; Eladl, M.A.; Mohamed, A.S.; El-Shafey, M.; Ali, H.S.; Zaitone, S.A.; Alomar, S.Y.; Alqahtani, S.A.M.; Aloyouni, S.Y.; et al. Leflunomide Induces Dose-Dependent Lung Injury in Mice via Stimulating Vimentin and NLRP3 Inflammasome Production. Front. Pharmacol. 2021, 12, 649. [Google Scholar] [CrossRef]
- Nakafero, G.; Grainge, M.J.; Card, T.; Mallen, C.D.; Zhang, W.; Doherty, M.; Taal, M.W.; Aithal, G.P.; Abhishek, A. What Is the Incidence of Methotrexate or Leflunomide Discontinuation Related to Cytopenia, Liver Enzyme Elevation or Kidney Function Decline? Rheumatology 2021, 60, 5785–5794. [Google Scholar] [CrossRef]
- Evans, S.J.; Webb, D.; Lawson, T.M.; Siebert, S. Renal Tubular Acidosis Associated with Leflunomide. Rheumatology 2007, 46, 1040–1041. [Google Scholar] [CrossRef] [Green Version]
- Haydar, A.A.; Hujairi, N.; Kirkham, B.; Hangartner, R.; Goldsmith, D.J. Chronic Overdose of Leflunomide Inducing Interstitial Nephritis. Nephrol. Dial. Transplant. 2004, 19, 1334–1335. [Google Scholar] [CrossRef]
- Hurtado, M.; Silva, O.R.B.; Santacruz, F. Nefritis túbulo intersticial por leflunomida. Rev. Colomb. Nefrol. 2016, 3, 132–136. [Google Scholar] [CrossRef]
- Pinto, B.; Dhir, V.; Krishnan, S.; Nada, R. Leflunomide-Induced DRESS Syndrome with Renal Involvement and Vasculitis. Clin. Rheumatol. 2013, 32, 689–693. [Google Scholar] [CrossRef]
- Azab, A.; Fetouh, F.; Albasha, M. Nephro-Protective Effects of Curcumin, Rosemary and Propolis against Gentamicin Induced Toxicity in Guinea Pigs: Morphological and Biochemical Study. Am. J. Clin. Exp. Med. 2014, 2, 28–35. [Google Scholar] [CrossRef] [Green Version]
- Balas, M.; Popescu Din, I.M.; Hermenean, A.; Cinteza, L.O.; Dinischiotu, A. Exposure to Iron Oxide Nanoparticles Coated with Phospholipid-Based Polymeric Micelles Induces Renal Transitory Biochemical and Histopathological Changes in Mice. Materials 2021, 14, 2605. [Google Scholar] [CrossRef]
- Haschek, W.M.; Rousseaux, C.G.; Wallig, M.A.; Bolon, B.; Ochoa, R. Haschek and Rousseaux’s Handbook of Toxicologic Pathology; Academic Press: Cambridge, MA, USA, 2013. [Google Scholar]
- Balaji, K.; Vijayakumar, J.; Sankaran, P.K.; Senthilkumar, S.; Vijayaraghavan, R.; Selvaraj, J.; Yuvaraj, M.F. Molecular Studies on the Nephroprotective Potential of Celastrus Paniculatus against Lead-Acetate-Induced Nephrotoxicity in Experimental Rats: Role of the PI3K/AKT Signaling Pathway. Molecules 2021, 26, 6647. [Google Scholar] [CrossRef]
- Min, H.S.; Lee, J.E.; Ghee, J.Y.; Kang, Y.S.; Cha, J.J.; Han, J.Y.; Han, S.Y.; Cha, D.R. A Novel Dipeptidyl Peptidase-4 Inhibitor DA-1229 Ameliorates Tubulointerstitial Fibrosis in Cyclosporine Nephrotoxicity in Mice. Life 2021, 11, 251. [Google Scholar] [CrossRef]
- Bushau-Sprinkle, A.M.; Barati, M.T.; Zheng, Y.; Watson, W.H.; Gagnon, K.B.; Khundmiri, S.J.; Kitterman, K.T.; Clark, B.J.; Siskind, L.J.; Doll, M.A.; et al. Na/H Exchange Regulatory Factor 1 Deficient Mice Show Evidence of Oxidative Stress and Altered Cisplatin Pharmacokinetics. Antioxidants 2021, 10, 1036. [Google Scholar] [CrossRef]
- Perazella, M.A. Pharmacology behind Common Drug Nephrotoxicities. Clin. J. Am. Soc. Nephrol. 2018, 13, 1897–1908. [Google Scholar] [CrossRef]
- Roberts, A.B.; Wakefield, L.M. The Two Faces of Transforming Growth Factor β in Carcinogenesis. Proc. Natl. Acad. Sci. USA 2003, 100, 8621–8623. [Google Scholar] [CrossRef] [Green Version]
- Meulmeester, E.; ten Dijke, P. The Dynamic Roles of TGF-β in Cancer. J. Pathol. 2011, 223, 206–219. [Google Scholar] [CrossRef]
- Inman, G.J. Switching TGFβ from a Tumor Suppressor to a Tumor Promoter. Curr. Opin. Genet. Dev. 2011, 21, 93–99. [Google Scholar] [CrossRef]
- Huang, T.; David, L.; Mendoza, V.; Yang, Y.; Villarreal, M.; De, K.; Sun, L.; Fang, X.; López-Casillas, F.; Wrana, J.L.; et al. TGF-β Signalling Is Mediated by Two Autonomously Functioning TβRI:TβRII Pairs. EMBO J. 2011, 30, 1263–1276. [Google Scholar] [CrossRef] [Green Version]
- Groppe, J.; Hinck, C.S.; Samavarchi-Tehrani, P.; Zubieta, C.; Schuermann, J.P.; Taylor, A.B.; Schwarz, P.M.; Wrana, J.L.; Hinck, A.P. Cooperative Assembly of TGF-β Superfamily Signaling Complexes Is Mediated by Two Disparate Mechanisms and Distinct Modes of Receptor Binding. Mol. Cell 2008, 29, 157–168. [Google Scholar] [CrossRef]
- Feng, X.-H.; Derynck, R. Specificity and versatility in tgf-β signaling through smads. Annu. Rev. Cell Dev. Biol. 2005, 21, 659–693. [Google Scholar] [CrossRef] [Green Version]
- Heldin, C.-H.; Moustakas, A. Role of Smads in TGFβ Signaling. Cell Tissue Res. 2012, 347, 21–36. [Google Scholar] [CrossRef]
- Massagué, J.; Seoane, J.; Wotton, D. Smad Transcription Factors. Genes Dev. 2005, 19, 2783–2810. [Google Scholar] [CrossRef] [Green Version]
- Ramesh, S.; Qi, X.-J.; Wildey, G.M.; Robinson, J.; Molkentin, J.; Letterio, J.; Howe, P.H. TGFβ-Mediated BIM Expression and Apoptosis Are Regulated through SMAD3-Dependent Expression of the MAPK Phosphatase MKP2. EMBO Rep. 2008, 9, 990–997. [Google Scholar] [CrossRef] [Green Version]
- Spender, L.C.; O’Brien, D.I.; Simpson, D.; Dutt, D.; Gregory, C.D.; Allday, M.J.; Clark, L.J.; Inman, G.J. TGF-β Induces Apoptosis in Human B Cells by Transcriptional Regulation of BIK and BCL-XL. Cell Death Differ. 2009, 16, 593–602. [Google Scholar] [CrossRef] [Green Version]
- Meng, X.; Nikolic-Paterson, D.J.; Lan, H.Y. TGF-β: The Master Regulator of Fibrosis. Nat. Rev. Nephrol. 2016, 12, 325–338. [Google Scholar] [CrossRef]
- Sharma, K.; Ziyadeh, F.N.; Alzahabi, B.; McGowan, T.A.; Kapoor, S.; Kurnik, B.R.C.; Kurnik, P.B.; Weisberg, L.S. Increased Renal Production of Transforming Growth Factor-Β1 in Patients with Type II Diabetes. Diabetes 1997, 46, 854–859. [Google Scholar] [CrossRef]
- Beckerman, R.; Prives, C. Transcriptional Regulation by P53. Cold Spring Harb. Perspect. Biol. 2010, 2, a000935. [Google Scholar] [CrossRef] [Green Version]
- Riley, T.; Sontag, E.; Chen, P.; Levine, A. Transcriptional Control of Human P53-Regulated Genes. Nat. Rev. Mol. Cell Biol. 2008, 9, 402–412. [Google Scholar] [CrossRef]
- Soto-Cruz, I.; Legorreta-Herrera, M. Analysis of a P53 Mutation Associated with Cancer Susceptibility for Biochemistry and Genetic Laboratory Courses. Biochem. Mol. Biol. Educ. 2009, 37, 236–242. [Google Scholar] [CrossRef]
- Levine, A.J. Reviewing the Future of the P53 Field. Cell Death Differ. 2018, 25, 1–2. [Google Scholar] [CrossRef] [Green Version]
- Lawrence, M.S.; Stojanov, P.; Mermel, C.H.; Robinson, J.T.; Garraway, L.A.; Golub, T.R.; Meyerson, M.; Gabriel, S.B.; Lander, E.S.; Getz, G. Discovery and Saturation Analysis of Cancer Genes across 21 Tumour Types. Nature 2014, 505, 495–501. [Google Scholar] [CrossRef] [Green Version]
- Levine, A.J.; Oren, M. The First 30 Years of P53: Growing Ever More Complex. Nat. Rev. Cancer 2009, 9, 749–758. [Google Scholar] [CrossRef] [Green Version]
- Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the P53 Network. Nature 2000, 408, 307–310. [Google Scholar] [CrossRef]
- Elston, R.; Inman, G.J. Crosstalk between P53 and TGF-β Signalling. J. Signal Transduct. 2012, 2012, e294097. [Google Scholar] [CrossRef] [Green Version]
- Wyllie, F.S.; Dawson, T.; Bond, J.A.; Goretzki, P.; Game, S.; Prime, S.; Wynford-Thomas, D. Correlated Abnormalities of Transforming Growth Factor-Β1 Response and P53 Expression in Thyroid Epithelial Cell Transformation. Mol. Cell. Endocrinol. 1991, 76, 13–21. [Google Scholar] [CrossRef]
- Higgins, S.P.; Tang, Y.; Higgins, C.E.; Mian, B.; Zhang, W.; Czekay, R.-P.; Samarakoon, R.; Conti, D.J.; Higgins, P.J. TGF-Β1/P53 Signaling in Renal Fibrogenesis. Cell. Signal. 2018, 43, 1–10. [Google Scholar] [CrossRef]
- KEGG: Kyoto Encyclopedia of Genes and Genomes. Available online: https://www.genome.jp/kegg/ (accessed on 12 May 2022).
- Home-Reactome Pathway Database. Available online: https://reactome.org/ (accessed on 12 May 2022).
- Xu, Q.; Ming, Z.; Dart, A.M.; Du, X.-J. Optimizing Dosage of Ketamine and Xylazine in Murine Echocardiography. Clin. Exp. Pharmacol. Physiol. 2007, 34, 499–507. [Google Scholar] [CrossRef]
- Gargiulo, S.; Greco, A.; Gramanzini, M.; Esposito, S.; Affuso, A.; Brunetti, A.; Vesce, G. Mice Anesthesia, Analgesia, and Care, Part I: Anesthetic Considerations in Preclinical Research. ILAR J. 2012, 53, E55–E69. [Google Scholar] [CrossRef] [Green Version]
- Bancroft, J.D.; Gamble, M. Theory and Practice of Histological Techniques; Elsevier: Amsterdam, The Netherlands, 2008. [Google Scholar]
- Klopfleisch, R. Multiparametric and Semiquantitative Scoring Systems for the Evaluation of Mouse Model Histopathology—A Systematic Review. BMC Vet. Res. 2013, 9, 123. [Google Scholar] [CrossRef] [Green Version]
- Asa, S.A.; EL-Nahass, E.-S.; Moselhy, W.A.; Hassan, N.E.-H.Y.; Hassan, A.A. Aflatoxin Induced Renal Toxicity in Albino Rats and the Ameliorative Effect of Green Tea Aqueous Extract: Histological, Morphometric and Immuno-Histochemical Study. J. Exp. Appl. Anim. Sci. 2018, 2, 273–285. [Google Scholar] [CrossRef]
- Cekmen, M.; Otunctemur, A.; Ozbek, E.; Cakir, S.S.; Dursun, M.; Polat, E.C.; Somay, A.; Ozbay, N. Pomegranate Extract Attenuates Gentamicin-Induced Nephrotoxicity in Rats by Reducing Oxidative Stress. Ren. Fail. 2013, 35, 268–274. [Google Scholar] [CrossRef] [Green Version]
- Breedveld, F.C.; Dayer, J.-M. Leflunomide: Mode of Action in the Treatment of Rheumatoid Arthritis. Ann. Rheum. Dis. 2000, 59, 841–849. [Google Scholar] [CrossRef]
- Van Riel, P.L.C.M.; Smolen, J.S.; Emery, P.; Kalden, J.R.; Dougados, M.; Strand, C.V.; Breedveld, F.C. Leflunomide: A Manageable Safety Profile. J. Rheumatol. Suppl. 2004, 71, 21–24. [Google Scholar]
- Toyokawa, Y.; Kingetsu, I.; Yasuda, C.; Yasuda, J.; Yoshida, K.; Kurosaka, D.; Yamada, A. Pancytopenia, Including Macrocytic Anemia, Associated with Leflunomide in a Rheumatoid Arthritis Patient. Mod. Rheumatol. 2007, 17, 436–440. [Google Scholar] [CrossRef]
- Kemp, E.; Nielsen, H.; Petersen, L.J.; Gam, A.N.; Dahlager, J.; Horn, T.; Larsen, S.; Olsen, S. Newer Immunomodulating Drugs in Rheumatoid Arthritis May Precipitate Glomerulonephritis. Clin. Nephrol. 2001, 55, 87–88. [Google Scholar]
- Pliquett, R.U.; Lübbert, C.; Schäfer, C.; Girndt, M. Thrombotic Microangiopathy and Liver Toxicity Due to a Combination Therapy of Leflunomide and Methotrexate: A Case Report. J. Med. Case Rep. 2020, 14, 26. [Google Scholar] [CrossRef]
- Rozman, B. Clinical Pharmacokinetics of Leflunomide. Clin. Pharmacokinet. 2002, 41, 421–430. [Google Scholar] [CrossRef]
- Boelsterli, U.A.; Lim, P.L.K. Mitochondrial Abnormalities—A Link to Idiosyncratic Drug Hepatotoxicity? Toxicol. Appl. Pharmacol. 2007, 220, 92–107. [Google Scholar] [CrossRef]
- Suissa, S.; Ernst, P.; Hudson, M.; Bitton, A.; Kezouh, A. Newer Disease-Modifying Antirheumatic Drugs and the Risk of Serious Hepatic Adverse Events in Patients with Rheumatoid Arthritis. Am. J. Med. 2004, 117, 87–92. [Google Scholar] [CrossRef]
- Van Roon, E.N.; Jansen, T.L.T.A.; Houtman, N.M.; Spoelstra, P.; Brouwers, J.R. Leflunomide for the Treatment of Rheumatoid Arthritis in Clinical Practice. Drug Saf. 2004, 27, 345–352. [Google Scholar] [CrossRef]
- Weinblatt, M.E.; Dixon, J.A.; Falchuk, K.R. Serious Liver Disease in a Patient Receiving Methotrexate and Leflunomide. Arthritis Rheum. 2000, 43, 2609–2611. [Google Scholar] [CrossRef] [3.0.CO;2-R/pdf" target='_blank'>Green Version]
- Fabregat, I.; Moreno-Càceres, J.; Sánchez, A.; Dooley, S.; Dewidar, B.; Giannelli, G.; ten Dijke, P.; on behalf of the IT-LIVER Consortium. TGF-β Signalling and Liver Disease. FEBS J. 2016, 283, 2219–2232. [Google Scholar] [CrossRef] [Green Version]
- Tsuchida, T.; Friedman, S.L. Mechanisms of Hepatic Stellate Cell Activation. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 397–411. [Google Scholar] [CrossRef]
- Lee, S.-W.; Park, H.-J.; Kim, B.K.; Han, K.-H.; Lee, S.-K.; Kim, S.U.; Park, Y.-B. Leflunomide Increases the Risk of Silent Liver Fibrosis in Patients with Rheumatoid Arthritis Receiving Methotrexate. Arthritis Res. Ther. 2012, 14, R232. [Google Scholar] [CrossRef] [Green Version]
- Chang, K.-W.; Zhang, X.; Lin, S.-C.; Lin, Y.-C.; Li, C.-H.; Akhrymuk, I.; Lin, S.-H.; Lin, C.-C. Atractylodin Suppresses TGF-β-Mediated Epithelial-Mesenchymal Transition in Alveolar Epithelial Cells and Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice. Int. J. Mol. Sci. 2021, 22, 11152. [Google Scholar] [CrossRef]
- Schiff, M.H.; Whelton, A. Renal Toxicity Associated with Disease-Modifying Antirheumatic Drugs Used for the Treatment of Rheumatoid Arthritis. Semin. Arthritis Rheum. 2000, 30, 196–208. [Google Scholar] [CrossRef]
- Clark, D.A.; Coker, R. Transforming Growth Factor-Beta (TGF-Beta). Int. J. Biochem. Cell Biol. 1998, 30, 293–298. [Google Scholar] [CrossRef]
- Ma, T.-T.; Meng, X.-M. TGF-β/Smad and Renal Fibrosis. In Renal Fibrosis: Mechanisms and Therapies; Liu, B.-C., Lan, H.-Y., Lv, L.-L., Eds.; Advances in Experimental Medicine and Biology; Springer: Singapore, 2019; pp. 347–364. ISBN 9789811388712. [Google Scholar]
- Isaka, Y. Targeting TGF-β Signaling in Kidney Fibrosis. Int. J. Mol. Sci. 2018, 19, 2532. [Google Scholar] [CrossRef] [Green Version]
- Dewald, O.; Zymek, P.; Winkelmann, K.; Koerting, A.; Ren, G.; Abou-Khamis, T.; Michael, L.H.; Rollins, B.J.; Entman, M.L.; Frangogiannis, N.G. CCL2/Monocyte Chemoattractant Protein-1 Regulates Inflammatory Responses Critical to Healing Myocardial Infarcts. Circ. Res. 2005, 96, 881–889. [Google Scholar] [CrossRef] [Green Version]
- Böttinger, E.P.; Bitzer, M. TGF-ß Signaling in Renal Disease. J. Am. Soc. Nephrol. 2002, 13, 2600–2610. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Aljohani, A.A.; Alqarni, Y.S.; Alrashidi, M.N.; Aljuhani, M.H.; Shehata, S.A.; El-Kherbetawy, M.K.; Prabahar, K.; Alshaman, R.; Alattar, A.; Helaly, A.M.N.; et al. The Anti-Rheumatic Drug, Leflunomide, Induces Nephrotoxicity in Mice via Upregulation of TGFβ-Mediated p53/Smad2/3 Signaling. Toxics 2022, 10, 274. https://doi.org/10.3390/toxics10050274
Aljohani AA, Alqarni YS, Alrashidi MN, Aljuhani MH, Shehata SA, El-Kherbetawy MK, Prabahar K, Alshaman R, Alattar A, Helaly AMN, et al. The Anti-Rheumatic Drug, Leflunomide, Induces Nephrotoxicity in Mice via Upregulation of TGFβ-Mediated p53/Smad2/3 Signaling. Toxics. 2022; 10(5):274. https://doi.org/10.3390/toxics10050274
Chicago/Turabian StyleAljohani, Alhanouf A., Yasmeen S. Alqarni, Maram N. Alrashidi, Maha H. Aljuhani, Shaimaa A. Shehata, Mohamed K. El-Kherbetawy, Kousalya Prabahar, Reem Alshaman, Abdullah Alattar, Ahmed M. N. Helaly, and et al. 2022. "The Anti-Rheumatic Drug, Leflunomide, Induces Nephrotoxicity in Mice via Upregulation of TGFβ-Mediated p53/Smad2/3 Signaling" Toxics 10, no. 5: 274. https://doi.org/10.3390/toxics10050274